Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments

Haematologica

Volumn 93, Issue 3, 2008, Pages 372-380

  De Stefano, Valerio ^a   Za, Tommaso ^a   Rossi, Elena ^a   Vannucchi, Alessandro M ^b   Ruggeri, Marco ^c   Elli, Elena ^d   Micò, Caterina ^e   Tieghi, Alessia ^f   Cacciola, Rossella R ^g   Santoro, Cristina ^h   Gerli, Giancarla ⁱ   Vianelli, Nicola ^j   Guglielmelli, Paola ^b   Pieri, Lisa ^b   Scognamiglio, Francesca ^c   Rodeghiero, Francesco ^c   Pogliani, Enrico M ^d   Finazzi, Guido ^e   Gugliotta, Luigi ^f   Marchioli, Roberto ^k   Leone, Giuseppe ^a   Barbui, Tiziano ^e   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k Consorzio Mario Negri Sud ^*  (Italy)

more..

Author keywords

Antiplatelet treatment; Cytoreductive treatment; Essential thrombocythemia; Oral anticoagulant treatment; Polycythemia vera; Recurrent thrombosis

Indexed keywords

ANAGRELIDE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BUSULFAN; HYDROXYUREA; INTERFERON; LOW MOLECULAR WEIGHT HEPARIN; PIPOBROMAN;

ACUTE CORONARY SYNDROME; ADULT; ARTERY THROMBOSIS; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MORBIDITY; PHLEBOTOMY; POLYCYTHEMIA VERA; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOCYTHEMIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PHLEBOTOMY; PLATELET AGGREGATION INHIBITORS; POLYCYTHEMIA VERA; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOSIS;

EID: 40849085151     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12053     Document Type: Article

References (33)

1. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128: 275-90.
2. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-64.
3. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224-32.
4. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8:556-62.
5. Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13:150-4.
6. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117:755-61.
7. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, longterm complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159-66.
8. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 2007;109:2310-3.
9. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with Polycythemia Vera. Blood 2007;109:2446-52.
10. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135-6.
11. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden. Leukemia 2007;21: 1952-9.
12. Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002;71:1-6.
13. Randi ML, Rossi C, Fabris F, Menapace L, Girolami A. Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. Clin Appl Thromb Hemost 1999;5:131-5.
14. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23: 411-8.
15. Bachleitner-Hofmann T, Grumbeck E, Gisslinger H. Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients. Thromb Res 2003;112:229-32.
16. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, et al. General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005;130:174-95.
17. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-32.
18. Harrison C. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005;130:153-65.
19. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999;36 (Suppl 2): 9-13.
20. Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Green AR, et al. A polycythemia vera update: diagnosis, pathobiology, and treatment. Hematology (Am Soc Hematol Educ Program) 2000; 51-68.
21. WHO classification of the chronic myeloproliferative diseases (CMPD) polycythemia vera, chronic idiopathic myelofibrosis, essential thrombocythemia and CMPD unclassifiable. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours, vol. 3. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press; 2001:31-42.
22. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114-24.
23. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inceptioncohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
24. D'Alessandro G, Di Giovanni M, Roveyaz L, Iannizzi L, Compagnoni MP, Blanc S, et al. Incidence and prognosis of stroke in the Valle d'Aosta, Italy. First-year results of a community-based study. Stroke 1992;23:1712-5.
25. Lauria G, Gentile M, Fassetta G, Casetta I, Agnoli F, Andreotta G, et al. Incidence and prognosis of stroke in the Belluno province, Italy. First-year results of a community-based study. Stroke 1995;26:1787-93.
26. Di Chiara A, Chiarella F, Savonitto S, Lucci D, Bolognese L, De Servi S, et al. BLITZ Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003; 24:1616-29.
27. De Stefano V, Rossi E, Za T, Leone G. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. Semin Thromb Hemost 2006; 32:767-80.
28. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004;44:1945-56.
29. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
30. Hovens MMC, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006;4:1470-5.
31. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004; 439-56.
32. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyteplatelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523-30.
33. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.